Jef­frey Kindler’s Cen­trex­ion spells out pos­i­tive da­ta for its PhI­II-ready pain drug

The re­search team at Cen­trex­ion Ther­a­peu­tics, a Boston-based biotech start­up led by ex-Pfiz­er CEO Jef­frey Kindler, turned up at a sci­en­tif­ic con­fer­ence in Eu­rope to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER